Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
David J. Sullivan, Massimo Franchini, Michael J. Joyner, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
Jonathon W. Senefeld, Massimo Franchini, Carlo Mengoli, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2250647-e2250647
Open Access | Times Cited: 121
Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge
Daniele Focosi, Rodrigo Quiroga, Scott A. McConnell, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2264-2264
Open Access | Times Cited: 114
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients
Małgorzata Mikulska, Chiara Sepulcri, Chiara Dentone, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 2, pp. 280-286
Open Access | Times Cited: 87
Vaccines and therapeutics for immunocompromised patients with COVID-19
Shmuel Shoham, Carolina Batista, Yanis Ben Amor, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101965-101965
Open Access | Times Cited: 78
A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
Daniele Focosi, Arturo Casadevall
Viruses (2022) Vol. 14, Iss. 9, pp. 1999-1999
Open Access | Times Cited: 50
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
Daniele Focosi, Scott A. McConnell, Arturo Casadevall
Drug Resistance Updates (2022) Vol. 65, pp. 100882-100882
Open Access | Times Cited: 40
Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
Evan M. Bloch, Daniele Focosi, Shmuel Shoham, et al.
Clinical Infectious Diseases (2023) Vol. 76, Iss. 11, pp. 2018-2024
Open Access | Times Cited: 35
SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
Arturo Casadevall, Daniele Focosi
Journal of Clinical Investigation (2023) Vol. 133, Iss. 6
Open Access | Times Cited: 31
A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
Hassen Mohammed, Dan Duy Pham-Tran, Zi Yi Michelle Yeoh, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 224-224
Open Access | Times Cited: 30
Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
David J. Sullivan, Massimo Franchini, Jonathon W. Senefeld, et al.
Journal of General Virology (2023) Vol. 104, Iss. 5
Open Access | Times Cited: 30
Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy
Arturo Casadevall, Michael J. Joyner, Liise-anne Pirofski, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 5, pp. 381-395
Closed Access | Times Cited: 25
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 8
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 6
Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review
Santenna Chenchula, Krishna Chaitanya Amerneni, Mohan Krishna Ghanta, et al.
Virology (2023) Vol. 584, pp. 38-43
Open Access | Times Cited: 15
SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
Vaccines (2023) Vol. 11, Iss. 11, pp. 1634-1634
Open Access | Times Cited: 13
Long COVID across SARS-CoV-2 variants, lineages, and sublineages
Sergio Padilla, Christian Ledesma, Javier García-Abellán, et al.
iScience (2024) Vol. 27, Iss. 4, pp. 109536-109536
Open Access | Times Cited: 3
Double-blinded, randomised, placebo-controlled trial of convalescent plasma for COVID-19: analyses by neutralising antibodies homologous to recipients’ variants
Tuba Khawaja, Mikael Kajova, Iris Levonen, et al.
Infectious Diseases (2024) Vol. 56, Iss. 6, pp. 423-433
Open Access | Times Cited: 3
SARS-CoV-2 variant of concern fitness and adaptation in primary human airway epithelia
Rita M. Meganck, Caitlin E. Edwards, Michael L. Mallory, et al.
Cell Reports (2024) Vol. 43, Iss. 4, pp. 114076-114076
Open Access | Times Cited: 3
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
Han-Sol Park, Anna Yin, Caelan Barranta, et al.
JCI Insight (2024) Vol. 9, Iss. 8
Open Access | Times Cited: 3
Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report
Bénédicte Billi, Paul Cholley, Vincent Grobost, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
SARS-CoV-2 Omicron BA.1 Variant Infection of Human Colon Epithelial Cells
Avan Antia, David M. Alvarado, Qiru Zeng, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 634-634
Open Access | Times Cited: 3
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients
Sixten Körper, Beate Grüner, Daniel Zickler, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 24
Open Access | Times Cited: 20
Handheld NIR-to-NIR Platform for on-site evaluating protective neutralizing antibody against SARS-CoV-2 ancestral strain and Omicron variant after vaccination or infection
Qingwei Song, Lei Zhao, Weikang Mai, et al.
Biosensors and Bioelectronics (2023) Vol. 234, pp. 115353-115353
Open Access | Times Cited: 10
Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
David J. Sullivan, Massimo Franchini, Jonathon W. Senefeld, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 17
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
Massimo Franchini, Arturo Casadevall, Michael J. Joyner, et al.
Life (2023) Vol. 13, Iss. 1, pp. 134-134
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top